Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: Graft-versus-host disease and graft-versus-leukemia effect

Transplantation

Volumn 67, Issue 4, 1999, Pages 620-626

  Novitzky, Nicolas ^a,b   Thomas, Valda ^a   Hale, Geoffrey ^c   Waldmann, Herman ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; MESNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADENOVIRUS; ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; LUNG HEMORRHAGE; LYMPHOCYTE DEPLETION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; T LYMPHOCYTE; VIRUS INFECTION; WHOLE BODY RADIATION;

EID: 0033608388     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199902270-00022     Document Type: Article

References (46)

1. Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood 1987; 69: 1441.
2. Preisler HD, Anderson K, Rai K, et al. The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years. Br J Haematol 1989; 71: 189.
3. Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Blood 1990; 75: 27.
4. Jacobs P, Wood L, Novitzky N. Treatment of adult acute lymphoblastic leukaemia. Haematol Blood Transfus 1990; 33: 428.
5. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217.
6. Weisdorf DJ, Woods WG, Nesbit ME Jr, et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome. Br J Haematol 1994; 86: 62.
7. Weisdorf D, Haak R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024.
8. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459.
9. Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988; 109: 777.
10. Krischer J, Elfenbein G, Babington R, et al. Risk factors for cytomegalovirus pneumonia following allogeneic bone marrow transplantation after prophylaxis with intravenous immunoglobulin. Semin Hematol 1992; 29: 89.
11. Vallera DA, Soderling CC, Carlson GJ, Kersey JH. Bone marrow transplantation across major histocompatibility barriers in mice: effect of elimination of T cells from donor grafts by treatment with monoclonal Thy-1.2 plus complement or antibody alone. Transplantation 1981; 31: 218.
12. Vallera DA, Soderling CC, Carlson GJ, Kersey JH. Bone marrow transplantation across major histocompatibility barriers in mice: T cell requirements for engraftment in total lymphoid irradiation-conditioned recipients. Transplantation 1982; 33: 243.
13. Kernan NA, Collins NH, Cunningham I, et al. Prevention of GVHD in HLA-identical marrow grafts by removal of T cells with soybean agglutinin and SRBCs. Bone Marrow Transplant 1987; 2 (suppl 1): 13.
14. Waldmann H, Hale G, Cividalli G, et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984; ii: 483.
15. Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529.
16. Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard-risk leukemias. Lancet 1987; ii: 175.
17. Jacobs P, Wood L, Fullard L, Waldmann H, et al. T cell depletion by exposure to CAMPATH-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant 1994; 13: 763.
18. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol.1976; 33: 451.
19. Laporte JP, Douay L, Allieri A, et al. Expansion by folinic acid of the peripheral blood progenitor pool after chemotherapy: its use in autografting in acute leukaemia. Br J Haematol 1990; 74: 445.
20. Jacobs P, Wood L, Horak S. Collection and cryopreservation of human stem and progenitor cells for bone marrow transplantation. J Clin Apheresis 1991; 6: 54.
21. Thomas ED, Storb R, Clift RA, Fefer A, et al. Bone-marrow transplantation (second of 2 parts). N Engl J Med 1975; 292: 895.
22. Wingard JR, Curbow B, Baker F, Piantadosi S. Health, functional status, and employment of adult survivors of bone marrow transplantation. Ann Intern Med 1991; 114: 113.
23. 3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a leukemia intergroup study. Exp Hematol 1992; 20: 1194.
24. Keating MJ, Smith TL, Kantarjian H, et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988; 2(7): 403.
25. Frassoni F, Labopin M, Gluckman E, et al. Are patients with acute leukaemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Acute Leukaemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 1994; 8: 924.
26. Wilkins BS, Bostanci AG, Ryan MF. Haemopoietic regrowth after chemotherapy for acute leukaemia: an immunohistochemical study of bone marrow trephine biopsy specimens. J Clin Pathol 1993; 46: 915.
27. Duly SA, Jagger CJ. Bone marrow stromal cell changes in haematological malignancies. J Clin Pathol 1990; 43: 942.
28. Hale G, Waldmann H. CAMPATH-1 monoclonal antibodies in bone marrow transplantation. J Hematother 1994; 3: 15.
29. Bunjes D, Hertenstein, B, Wiesneth M, et al. In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexate. Bone Marrow Transplant 1995; 15(4): 563.
30. Willemze R, Richel DJ, Falkenburg JH, et al. In vivo use of CAMPATH-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation. Bone Marrow Transplant 1992; 9: 255.
31. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al. T-cell depleted allogeneic bone marrow transplantation as post-remission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1990; 91: 1083.
32. Heim S, Mitelman F. Cancer cytogenetics. New York: Alan Liss, 1987.
33. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86(4): 1261.
34. Ringden O, Labopin M, Gluckman E, et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis: Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1996; 18(5): 921.
35. Naparstek E, Or R, Nagler A, et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using CAMPATH-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995; 89(3): 506.
36. Storb R, Deeg HJ, Fisher L, Appelbaum F, et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988; 71: 293.
37. Vey N, Biaise D, Stoppa AM, et al. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant 1994; 14: 383.
38. Snyder DS, Chao NJ, Amylon MD, et al. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood 1993; 82: 2920.
39. Labar B, Masszi T, Morabito F, et al. Allogeneic bone marrow transplantation for acute leukaemia: IGCI experience. Bone Marrow Transplant 1996; 17: 1009.
40. Fagioli F, Bacigalupo A, Frassoni F, et al. Allogeneic bone marrow transplantation for acute myeloid leukaemia in first complete remission: the effect of FAB classification and GVHD prophylaxis. Bone Marrow Transplant 1994; 13: 247.
41. Sierra J, Brunet S, Granena A, et al. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. J Clin Oncol 1996; 14: 1353.
42. Fabian I, Flidel O, Gadish M, et al. Effects of CAMPATH-1 antibodies on the functional activity of monocytes and polymorphonuclear neutrophils. Exp Hematol 1993; 21: 1522.
43. Bomberg C, Singh-Jairam M, Rodey G, et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS sorted CD34* haematopoietic progenitors. Blood 1988; 71: 2588.
44. Roux E, Helg C, Dumont-Girard F, Chapuis B, et al. Analysis of T-cell repopulation after allogeneic marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 1996; 87: 3984.
45. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87(9): 3633.
46. Kolb HJ, Bender-Gotze C. Late complications after allogeneic bone marrow transplantation for leukaemia. Bone Marrow Transplant 1990; 6: 61.